Newsletter
How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation

Tradeoffs

How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation

April 14, 2022

How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation

After Medicare’s decision to restrict coverage of the controversial new Alzheimer’s drug Aduhelm, we look at how this one drug has forced the nation to reexamine how to balance the needs of desperate patients, incomplete evidence and larger economic realities.

Guests:

Phil Gutis, Alzheimer’s patient and advocate

Holly Fernandez Lynch, JD, MBe, John Russell Dickson, MD Presidential Assistant Professor of Medical Ethics, University of Pennsylvania

Have a look at some additional resources and a full transcript.

Support this type of journalism today, with a gift.

Follow us on Twitter


See acast.com/privacy for privacy and opt-out information.

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Join Our Newsletter

Proudly supported by:

cover
Age Like Royalty with Dr. Nakeisha Rodgers CEO of Dr. Nakeisha Rodgers LLC equips medical professionals with the tools needed to help savvy seniors age like royalty.